EOGT divergent transcript (EOGT-DT)

EOGT divergent transcript (EOGT-DT) is the RNA produced from a region near the EOGT gene locus and is classified as a *divergent transcript*, meaning it is transcribed in the opposite (antisense) direction from the protein-coding EOGT gene[2][4][5][7]. Divergent non-coding transcripts are a widespread genomic feature produced from active promoters; they are mostly unstable, often non-protein-coding RNAs, and their biological functions are generally obscure, though they may have roles in gene regulation or genome evolution[2][4][8][7]. Current gene annotation resources like GeneCards and NCBI report EOGT-DT as an RNA gene without a protein product and do not list any therapeutic targeting, molecular interactions, or disease associations for EOGT-DT specifically[5][7]. The canonical *protein-coding* EOGT gene encodes a glycosyltransferase involved in O-GlcNAc modification of EGF repeats but is unrelated to the non-coding divergent transcript[1][3][6]. Therefore, listing EOGT-DT as a therapeutic target is incorrect. "EOGT-DT" should not be confused with EOGT, the EGF domain-specific O-linked N-acetylglucosamine transferase, an enzyme of functional importance. EOGT-DT fits the category of a divergent, likely non-functional, non-coding RNA product with no demonstrated utility as a drug target or biomarker. There are no known aliases for EOGT-DT other than its systematic abbreviation. There is no evidence that EOGT-DT plays any direct role in disease, interacts with drugs, or is used as a biomarker. "EOGT divergent transcript" (EOGT-DT) is **not** a therapeutic target, nor a receptor, enzyme, transporter, or recognized functional RNA. Its inclusion as a target is likely a result of gene annotation artifacts or confusion with the EOGT protein-coding gene[5][7].

Other names

EOGT-DT